Evidence map›Paper›PMID 39658632›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Nephrotoxicity in locally advanced head and neck cancer: when the end justifies the means to preserve nutritional status during chemoradiation.

Sara Cardellini, Francesco Trevisani, Chiara Lucrezia Deantoni, Matteo Paccagnella, Andrea Pontara, Matteo Floris, Leone Giordano, Riccardo Caccialanza, Aurora Mirabile

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sara Cardellini *Clinical Nutrition, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Francesco Trevisani *Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Chiara Lucrezia DeantoniDepartment of Radiation Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Matteo PaccagnellaTranslational Oncology ARCO Foundation, Cuneo, Italy.
Andrea PontaraClinical Nutrition, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Matteo FlorisNephrology and Dialysis, Università Degli Studi Di Cagliari, G. Brotzu Hospital, Cagliari, Italy.
Leone GiordanoDepartment of Otorhinolaryngology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Riccardo CaccialanzaClinical Nutrition, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Aurora MirabileDepartment of Otorhinolaryngology, IRCCS San Raffaele Scientific Institute, Milan, Italy. mirabile.aurora@hsr.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin is a nephrotoxic agent able to damage renal function both in acute and chronic phases. Radiotherapy concomitant with cisplatin 100 mg/m

Indexed as

Antineoplastic AgentsChemoradiotherapyCisplatinGlomerular Filtration RateHead and Neck NeoplasmsNutritional StatusAcute Kidney InjuryAdultAgedFemaleHumansMaleMalnutritionMiddle AgedProspective StudiesAntineoplastic AgentsCisplatinAcute kidney diseaseAcute kidney injuryBody compositionChemotherapyHead and neck cancerHigh-dose cisplatinNutritional counsellingOral nutritional supplementsRadiotherapyRenal function

Identifiers

PMID39658632

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.